Disease Progression

Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.

WEST PALM BEACH, Fla. — Obesity was strongly associated with disability worsening, disease progression and declining quality of life in a cohort of adults diagnosed with multiple sclerosis, according to a presenter at ACTRIMS 2024.

Treatment with givinostat for ambulatory boys with Duchenne muscular dystrophy led to improved motion and reduced decline of muscle function and strength at 18 months, according to a poster at the 2024 MDA Clinical & Scientific Conference.

Durga S. Borkar, MD, MMCi, assistant professor of ophthalmology and director of clinical data science Duke University Eye Center, highlights the greatest areas of unmet need in geographic atrophy care and management.

A precision therapeutics company announced that the first participant has been dosed in a phase 2 clinical trial of a non-dopamine selective modulator to treat those with early-stage Parkinson’s disease.

Ocrevus infusions were effective in halting disease activity in Black and Hispanic individuals with relapsing forms of multiple sclerosis after 1 year, according to a study presented at ECTRIMS 2023.

For the prevention of rheumatoid arthritis to become feasible, it may be necessary to intervene as soon as possible in the pre-RA course, although the specific timing remains unclear, according to a speaker at the EULAR 2023 Congress.

SAN DIEGO — A newly developed auditory-based test could assess and monitor cognitive function in previously untestable patients who are severely affected by MS, according to a poster at ACTRIMS 2023.

SAN DIEGO — Older men with MS who used androgen-modifying treatments experienced last disease activity at a later age compared with women and men who refrained from these treatments, according to a poster at ACTRIMS 2023.

SAN DIEGO — A new diagnosis of cardiovascular disease was linked to shortened time to disability progression and worsened outcomes in patients with MS, according to a poster presented at ACTRIMS 2023.